In our study, 3 of the 7 EGFR alteration cases are 19 exon deletion, which is recognized as a sensitive variant to EGFR tyrosinase inhibitor in lung cancer with 74% to 81% ORR[23]; Meanwhile, 4 of the 5 HER2 alteration cases are amplification, which can benefit from trastuzumab plus chemotherapy in breast, gastric, and other cancers.[24–28] Therefore, anti-EGFR or anti-HER2 targeted therapy may become alternative treatments for those OC patients with activated EGFR or HER2 variants after the failure of standard regimens. The gene discussed is ERBB2; the disease is cancer.